Gene Editing Company Takes Off in Premarket
Good morning Wake-Up Watchlisters! It’s the beginning of the week, and our Head Trading Tactician Nate Bear is giving you his weekly stocks to watch. This week he’s got his eye on two potential trade setups, plus some overarching strategy on the SPX. Click the image below to see this week’s stocks.
While you’re sipping coffee you’ll see stock futures dipped on Tuesday. Earnings season is underway, and investors will be focusing on megabanks like Goldman Sachs (GS) and Morgan Stanley (MS) after subpar results from other banks last week. Global leaders will also be gathering in the mountains of Davos, Switzerland this week for the World Economic Forum, with prospect of global recession among the topics.
With earnings season on the horizon, it’s important to use the best practices for making gains in the market. We have a strategy in The War Room that’s proven to help members double their money (or more) in 24 hours – regardless of whether a stock goes up or down.
Here’s a look at the top-moving stocks this morning.
National Instruments Corporation (Nasdaq: NATI)
National Instruments Corporation is up 11.77% premarket after it was announced that Emerson (NYSE: EMR) submitted a proposal to acquire NI for $53 per share in cash at an implied value of $7.6 billion. The proposal represents an improvement over an initial $48 per share and will provide immediate cash value for all NI shareholders.
Calyxt, Inc. (Nasdaq: CLXT)
Calyxt Inc. is up 62.09% premarket after the technology platform announced a merger with Cibus, with the goal to create an industry-leading gene editing and trait licensing company. The merger will establish one of the world’s most sophisticated facilities for trait development and next-generation plant breeding.
We’re on the cusp of the next big tech revolution, and our friend Andy Snyder wants you to know about this up-and-coming virtual company. He believes this fully immersive service could be at the center of the next big tech boom, and it’s trading for less than $1 right now.
Viveve Medical (Nasdaq: VIVE)
Viveve Medical is down 56.98 % premarket after the women’s health and treatment of female stress urinary incontinence’s latest PURSUIT study did not meet its primary endpoint of achieving a statistically significant higher proportion who experienced greater than 50% reduction in urine leakage compared to the baseline. The proportion of patients with over a 50% reduction in leakage in the active group was 49.8%.
When it delivers results, medical companies can sometimes provide the biggest surges in the market. Our friend Alexander Green has a proven track record of finding these buying opportunities, and right now he’s pounding the table on a $3 company he’s calling the “most incredible investment opportunity I’ve seen in 37 years.”
Those are the top market movers today.
The Wake-Up Watchlist Research Team